Mirtazapina Flas Cinfamed (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas Cinfamed, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral formulation for systemic use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapina Flas Cinfamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used primarily within the depressive disorder therapeutic pathway. - Major depressive disorder: alleviates depressive symptoms and improves mood in adults. - Treatment‑resistant depression: may be added when first‑line agents are insufficient. - Co‑morbid anxiety with depression: can reduce anxiety symptoms alongside depressive improvement.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness: feeling unusually sleepy. - Increased appetite and weight gain: heightened hunger leading to weight increase. - Dry mouth: reduced salivation. - Constipation: difficulty passing stools. - Dizziness: sensation of light‑headedness. - Edema: mild swelling of extremities.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Severe hypersensitivity: rash, swelling, or anaphylaxis. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Hepatotoxicity: liver enzyme abnormalities. - Seizures: occurrence of convulsive episodes. - Serotonin syndrome: signs of excessive serotonergic activity.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown excretion; consider alternatives. - Elderly: start low, monitor for sedation and falls. - Hepatic impairment: dose adjustment may be required. - Concomitant CNS depressants: increase risk of excessive sedation. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Potent CYP1A2 inhibitors (e.g., fluvoxamine): may raise mirtazapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): profound sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tamoxifen): altered metabolism. - Anticholinergic agents: additive dry mouth and constipation. - QT‑prolonging drugs: potential cardiac rhythm effects.